Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients
Prognostic biomarkers derived from complete blood count (CBC) have received marked interest as an indirect measure of the inflammatory pressure in cancers such as metastatic melanoma. Here, we evaluated the novel pan-immune-inflammation value (PIV) and the frequently assessed neutrophil/lymphocyte r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/18/4410 |
| _version_ | 1797490271123931136 |
|---|---|
| author | Thilo Gambichler Andreas Stang Rita Mansour Christina H. Scheel Celine Nick Nessr Abu Rached Jürgen C. Becker Laura Susok |
| author_facet | Thilo Gambichler Andreas Stang Rita Mansour Christina H. Scheel Celine Nick Nessr Abu Rached Jürgen C. Becker Laura Susok |
| author_sort | Thilo Gambichler |
| collection | DOAJ |
| description | Prognostic biomarkers derived from complete blood count (CBC) have received marked interest as an indirect measure of the inflammatory pressure in cancers such as metastatic melanoma. Here, we evaluated the novel pan-immune-inflammation value (PIV) and the frequently assessed neutrophil/lymphocyte ratio (NLR) in a large cohort of patients with cutaneous melanoma (CM) without distant metastases (stages I to III). PIV and NLR were calculated at CM diagnosis. Healthy controls were also included. We used the Kaplan–Meier method to estimate crude survival probabilities and used Cox proportional hazards regression for multiple adjustment of hazard ratios. We observed that higher PIV (HR: 1.72, 95% CI 1.14 to 2.58 and HR: 1.696, 95% CI 1.029 to 2.795, respectively) and NLR (HR: 1.70, 95% CI 1.10 to 2.62) values were associated with CM relapse and CM-specific death in the crude analysis. However, when adjusting for potential confounders, in particular age and tumor thickness, the total effect of PIV and NLR on CM-relapse-free (HR: 1.28, 95% CI 0.83 to 1.98 and HR: 1.26, 95% CI 0.80 to 1.98, respectively) and CM-specific survival (HR: 1.36, 95% CI 0.80 to 2.30 and HR: 1.37, 95% CI 0.80 to 2.33, respectively) was substantially reduced. However, both PIV and NLR were positively correlated with age and tumor thickness, which are important independent predictors for CM relapse and CM-specific death. In conclusion, in stage I to III CM patients PIV as well as NLR appear to be confounded by age and tumor thickness and probably have no potential to further improve the prediction of survival of stage I to III CM patients beyond standard prognostic factors. |
| first_indexed | 2024-03-10T00:30:37Z |
| format | Article |
| id | doaj.art-7fd1225ae85b41ddbc34cff3035d2d2e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:30:37Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7fd1225ae85b41ddbc34cff3035d2d2e2023-11-23T15:26:48ZengMDPI AGCancers2072-66942022-09-011418441010.3390/cancers14184410Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma PatientsThilo Gambichler0Andreas Stang1Rita Mansour2Christina H. Scheel3Celine Nick4Nessr Abu Rached5Jürgen C. Becker6Laura Susok7Skin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanyInstitute of Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, 45147 Essen, GermanySkin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanySkin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanySkin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanySkin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanyDepartment of Dermatology, Translational Skin Cancer Research, German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, University Duisburg-Essen, 45147 Essen, GermanySkin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, GermanyPrognostic biomarkers derived from complete blood count (CBC) have received marked interest as an indirect measure of the inflammatory pressure in cancers such as metastatic melanoma. Here, we evaluated the novel pan-immune-inflammation value (PIV) and the frequently assessed neutrophil/lymphocyte ratio (NLR) in a large cohort of patients with cutaneous melanoma (CM) without distant metastases (stages I to III). PIV and NLR were calculated at CM diagnosis. Healthy controls were also included. We used the Kaplan–Meier method to estimate crude survival probabilities and used Cox proportional hazards regression for multiple adjustment of hazard ratios. We observed that higher PIV (HR: 1.72, 95% CI 1.14 to 2.58 and HR: 1.696, 95% CI 1.029 to 2.795, respectively) and NLR (HR: 1.70, 95% CI 1.10 to 2.62) values were associated with CM relapse and CM-specific death in the crude analysis. However, when adjusting for potential confounders, in particular age and tumor thickness, the total effect of PIV and NLR on CM-relapse-free (HR: 1.28, 95% CI 0.83 to 1.98 and HR: 1.26, 95% CI 0.80 to 1.98, respectively) and CM-specific survival (HR: 1.36, 95% CI 0.80 to 2.30 and HR: 1.37, 95% CI 0.80 to 2.33, respectively) was substantially reduced. However, both PIV and NLR were positively correlated with age and tumor thickness, which are important independent predictors for CM relapse and CM-specific death. In conclusion, in stage I to III CM patients PIV as well as NLR appear to be confounded by age and tumor thickness and probably have no potential to further improve the prediction of survival of stage I to III CM patients beyond standard prognostic factors.https://www.mdpi.com/2072-6694/14/18/4410cutaneous melanomapan-immune-inflammation valueneutrophil/lymphocyte ratiobiomarkers |
| spellingShingle | Thilo Gambichler Andreas Stang Rita Mansour Christina H. Scheel Celine Nick Nessr Abu Rached Jürgen C. Becker Laura Susok Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients Cancers cutaneous melanoma pan-immune-inflammation value neutrophil/lymphocyte ratio biomarkers |
| title | Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients |
| title_full | Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients |
| title_fullStr | Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients |
| title_full_unstemmed | Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients |
| title_short | Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients |
| title_sort | prognostic potential of the baseline pan immune inflammation value and neutrophil lymphocyte ratio in stage i to iii melanoma patients |
| topic | cutaneous melanoma pan-immune-inflammation value neutrophil/lymphocyte ratio biomarkers |
| url | https://www.mdpi.com/2072-6694/14/18/4410 |
| work_keys_str_mv | AT thilogambichler prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT andreasstang prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT ritamansour prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT christinahscheel prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT celinenick prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT nessraburached prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT jurgencbecker prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients AT laurasusok prognosticpotentialofthebaselinepanimmuneinflammationvalueandneutrophillymphocyteratioinstageitoiiimelanomapatients |